SEX DIFFERENCES IN CARDIOVASCULAR DISEASE OUTCOMES IN RESPONSE TO FENOFIBRATE THERAPY IN TYPE 2 DIABETIC PATIENTS IN THE ACCORD LIPID STUDY

Coronary artery disease is the leading cause of death in Type 2 diabetes patients (T2D) with lipid abnormalities. Fibrates have emerged as second-line agents to reduce circulating triglycerides and elevate HDL-C. The ACCORD Lipid study, a subset of the ACCORD trial([NCT00000620][1]), investigated